HC Wainwright & Co. Reiterates Buy on Milestone Pharmaceuticals, Maintains $25 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Patrick Trucchio has reiterated a Buy rating on Milestone Pharmaceuticals (NASDAQ:MIST), maintaining a $25 price target.
March 22, 2024 | 6:07 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Milestone Pharmaceuticals receives a reiterated Buy rating and a maintained $25 price target from HC Wainwright & Co.
The reiteration of a Buy rating and maintenance of a $25 price target by a reputable analyst firm like HC Wainwright & Co. typically signals strong confidence in the company's future performance. This endorsement is likely to positively influence investor sentiment and potentially drive up the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100